Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Mohit Anand

Internal Medicine Locust Grove, VA Medical Doctor

NPI 1912976077 CMS profile 267825

4376 Germanna Hwy, Locust Grove, VA 22508

Open in the dashboard

General payments

$2,293

127 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Mohit Anand of Locust Grove, VA is reported in the CMS Open Payments database as having received $2,293 across 127 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $80 3
2021 General $562 29
2020 General $760 44
2019 General $891 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohit Anand
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Mohit Anand were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Mohit Anand Internal Medicine median Middle half National median
2019 $891 $159 $48–$570 $163
2020 $760 $119 $33–$402 $114
2021 $562 $135 $37–$521 $132
2022 $80 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Amgen Inc. $374 18 payments
  2. Novo Nordisk Inc $281 17 payments
  3. AstraZeneca Pharmaceuticals LP $228 12 payments
  4. AbbVie, Inc. $203 8 payments
  5. Amarin Pharma Inc. $143 8 payments
  6. Esperion Therapeutics, Inc. $115 5 payments
  7. Sunovion Pharmaceuticals Inc. $101 5 payments
  8. Merck Sharp & Dohme Corporation $98 8 payments
  9. Pfizer Inc. $93 6 payments
  10. Allergan Inc. $64 4 payments
  11. Other $593 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,280 126 payments
  2. Education $14 1 payment
Products named General payments · program years 2019–2022
  1. AIMOVIG $254 10 payments
  2. Ozempic $156 9 payments
  3. FARXIGA $133 6 payments
  4. RYBELSUS $128 7 payments
  5. UBRELVY $127 5 payments
  6. NEXLETOL $115 5 payments
  7. Vascepa $109 6 payments
  8. SYMBICORT $103 4 payments
  9. EVENITY $101 7 payments
  10. Prolia $101 7 payments
  11. Other $1,761 112 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 140 drugs

Part D claims

7,895

Median for Internal Medicine: 777

Drug cost

$542,059

Median for Internal Medicine: $73,373

Branded share of claims

20.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 78 $88,872
Ozempic Semaglutide Brand 44 $55,150
Jardiance Empagliflozin Brand 30 $50,434
Trulicity Dulaglutide Brand 33 $42,095
Januvia Sitagliptin Phosphate Brand 25 $38,900
Mounjaro Tirzepatide Brand 29 $29,464
Farxiga Dapagliflozin Propanediol Brand 14 $22,998
Janumet Sitagliptin Phos/Metformin Hcl Brand 11 $18,355
Xarelto Rivaroxaban Brand 14 $14,284
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 67 $12,683

The 10 drugs with the highest cost, of 140 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$99,520

Of which drugs: $6,161

Medicare patients

520

Average age 75

Services billed

2,446

253 women, 267 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 40%
Diabetes 32%
Ischemic heart disease 26%
Atrial fibrillation 18%
Depression 17%
Chronic kidney disease 16%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 63 63 $3,886

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record